Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial - PubMed
5 hours ago
- #Cardiovascular Outcomes
- #Liver Fibrosis
- #Semaglutide
- Semaglutide reduced major adverse cardiovascular events (MACE) by 26% in patients with high risk of liver fibrosis (Fibrosis-4 score ≥ 1.3) compared to placebo.
- The drug also led to a 28% greater reduction in fatty liver index versus placebo, indicating decreased liver steatosis.
- This was a prespecified analysis of the SELECT trial, focusing on patients with atherosclerotic cardiovascular disease and obesity but without diabetes.